文献速递心力衰竭与心肌病

心血管生物标志物与射血分数保留型及降低型心力衰竭发病的关联

Association of Cardiovascular Biomarkers With Incident Heart Failure With Preserved and Reduced Ejection Fraction.
PubMed 文献 · JAMA Cardiol · 2018-01-01

结果显示,尿白蛋白/肌酐比值(UACR)和利钠肽与 HFpEF 显著相关,而利钠肽、UACR、高敏肌钙蛋白、胱抑素C、D-二聚体和C反应蛋白与 HFrEF 相关。利钠肽、高敏肌钙蛋白和CRP与 HFrEF 的关联强于 HFpEF。

要点

  • UACR和利钠肽与HFpEF发病显著相关。
  • 利钠肽、UACR、高敏肌钙蛋白、胱抑素C、D-二聚体、CRP与HFrEF相关。
  • 利钠肽、高敏肌钙蛋白和CRP与HFrEF关联更强。

核心结论

  • 肾功能不全、内皮功能障碍和炎症相关生物标志物与HFrEF发病相关,而仅利钠肽和UACR与HFpEF相关。

主要发现

  • 随访期间633人发生HFpEF,841人发生HFrEF。
  • 调整心衰临床危险因素后,UACR(HR 1.33;95% CI 1.20-1.48;P < .001)和利钠肽(HR 1.27;95% CI 1.16-1.40;P < .001)与HFpEF显著相关。
  • 高敏肌钙蛋白(HR 1.11;95% CI 1.03-1.19;P = .008)、纤溶酶原激活物抑制剂1(HR 1.22;95% CI 1.03-1.45;P = .02)和纤维蛋白原(HR 1.12;95% CI 1.03-1.22;P = .01)与HFpEF呈提示性关联。
  • 与HFrEF相关的生物标志物包括:利钠肽(HR 1.54;95% CI 1.41-1.68;P < .001)、UACR(HR 1.21;95% CI 1.11-1.32;P < .001)、高敏肌钙蛋白(HR 1.37;95% CI 1.29-1.46;P < .001)、胱抑素C(HR 1.19;95% CI 1.11-1.27;P < .001)、D-二聚体(HR 1.22;95% CI 1.11-1.35;P < .001)和CRP(HR 1.19;95% CI 1.11-1.28;P < .001)。
  • 直接比较时,利钠肽、高敏肌钙蛋白和CRP与HFrEF的关联强于HFpEF。

临床怎么用

  • 在社区人群中检测UACR和利钠肽有助于识别HFpEF高风险个体。
  • 利钠肽、高敏肌钙蛋白、胱抑素C、D-二聚体和CRP可提示HFrEF风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Nearly half of all patients with heart failure have preserved ejection fraction (HFpEF) as opposed to reduced ejection fraction (HFrEF), yet associations of biomarkers with future heart failure subtype are incompletely understood. OBJECTIVE: To evaluate the associations of 12 cardiovascular biomarkers with incident HFpEF vs HFrEF among adults from the general population. DESIGN, SETTING, AND PARTICIPANTS: This study included 4 longitudinal community-based cohorts: the Cardiovascular Health Study (1989-1990; 1992-1993 for supplemental African-American cohort), the Framingham Heart Study (1995-1998), the Multi-Ethnic Study of Atherosclerosis (2000-2002), and the Prevention of Renal and Vascular End-stage Disease study (1997-1998). Each cohort had prospective ascertainment of incident HFpEF and HFrEF. Data analysis was performed from June 25, 2015, to November 9, 2017. EXPOSURES: The following biomarkers were examined: N-terminal pro B-type natriuretic peptide or brain natriuretic peptide, high-sensitivity troponin T or I, C-reactive protein (CRP), urinary albumin to creatinine ratio (UACR), renin to aldosterone ratio, D-dimer, fibrinogen, soluble suppressor of tumorigenicity, galectin-3, cystatin C, plasminogen activator inhibitor 1, and interleukin 6. MAIN OUTCOMES AND MEASURES: Development of incident HFpEF and incident HFrEF. RESULTS: Among the 22 756 participants in these 4 cohorts (12 087 women and 10 669 men; mean [SD] age, 60 [13] years) in the study, during a median follow-up of 12 years, 633 participants developed incident HFpEF, and 841 developed HFrEF. In models adjusted for clinical risk factors of heart failure, 2 biomarkers were significantly associated with incident HFpEF: UACR (hazard ratio [HR], 1.33; 95% CI, 1.20-1.48; P < .001) and natriuretic peptides (HR, 1.27; 95% CI, 1.16-1.40; P < .001), with suggestive associations for high-sensitivity troponin (HR, 1.11; 95% CI, 1.03-1.19; P = .008), plasminogen activator inhibitor 1 (HR, 1.22; 95% CI, 1.03-1.45; P = .02), and fibrinogen (HR, 1.12; 95% CI, 1.03-1.22; P = .01). By contrast, 6 biomarkers were associated with incident HFrEF: natriuretic peptides (HR, 1.54; 95% CI, 1.41-1.68; P < .001), UACR (HR, 1.21; 95% CI, 1.11-1.32; P < .001), high-sensitivity troponin (HR, 1.37; 95% CI, 1.29-1.46; P < .001), cystatin C (HR, 1.19; 95% CI, 1.11-1.27; P < .001), D-dimer (HR, 1.22; 95% CI, 1.11-1.35; P < .001), and CRP (HR, 1.19; 95% CI, 1.11-1.28; P < .001). When directly compared, natriuretic peptides, high-sensitivity troponin, and CRP were more strongly associated with HFrEF compared with HFpEF. CONCLUSIONS AND RELEVANCE: Biomarkers of renal dysfunction, endothelial dysfunction, and inflammation were associated with incident HFrEF. By contrast, only natriuretic peptides and UACR were associated with HFpEF. These findings highlight the need for future studies focused on identifying novel biomarkers of the risk of HFpEF.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. de Boer RA, Nayor M, deFilippi CR, et al. Association of Cardiovascular Biomarkers With Incident Heart Failure With Preserved and Reduced Ejection Fraction. JAMA Cardiol. 2018. PMID: 29322198. doi:10.1001/jamacardio.2017.4987

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。